Saltar al contenido
Merck
Todas las fotos(2)

Key Documents

View All Documentation

C7287

Sigma-Aldrich

Canrenoic acid potassium salt

powder

Sinónimos:

17-Hydroxy-3-oxopregna-4,6-diene-21-carboxylic acid, Potassium canrenoate

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(2)

About This Item

Fórmula lineal:
C22H30O4K
Número de CAS:
2181-04-6
Peso molecular:
397.57
Número CE:
218-554-9
Número MDL:
MFCD05662375
Código UNSPSC:
12352106
ID de la sustancia en PubChem:
24892953
NACRES:
NA.77

formulario

powder

Nivel de calidad

100

color

light yellow to tan

cadena SMILES

[K].[H][C@]12CC[C@@]3(C)[C@@]([H])(CC[C@@]3(O)CCC(O)=O)[C@]1([H])C=CC4=CC(=O)CC[C@]24C

InChI

1S/C22H30O4.K.H/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21,26)12-8-19(24)25;;/h3-4,13,16-18,26H,5-12H2,1-2H3,(H,24,25);;/t16-,17+,18+,20+,21+,22-;;/m1../s1

Clave InChI

YLXFIHIYNGPPSF-HUHWECDNSA-N

Aplicación

Canrenoic acid potassium salt has been used as a human uridine 5′-diphospho (UDP)-glucuronosyltransferase inhibitor to study its effects on trifluoperazine (TFP) substrate selectivity. It has also been used to study its effects on the formation of aldosterone 18-glucuronide (ALDO 18β-G) in recombinant UDP-Glucuronosyltransferase-2B7 (UGT2B7), human liver (HLM) and human kidney cortical (HKCM) microsomes.

Acciones bioquímicas o fisiológicas

Competitive aldosterone receptor antagonist. Potassium canrenoate reduces the effects of aldosterone-induced increases in blood pressure and in cardiovascular fibrosis in animals with high sodium intake. It is used clinically for its anti-fibrotic effects. At higher doses it is genotoxic to liver and increases tumor incidence in rodent models.

Calidad

Aqueous solutions may contain some insoluble material.

Pictogramas

Exclamation mark
GHS07

Palabra de señalización

Warning

Frases de peligro

H302

Clasificaciones de peligro

Acute Tox. 4 Oral

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Equipo de protección personal

dust mask type N95 (US), Eyeshields, Gloves

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Helen C Atkinson et al.
American journal of physiology. Endocrinology and metabolism, 294(6), E1011-E1022 (2008-03-20)
The aim of this study was to investigate fast corticosteroid feedback of the hypothalamic-pituitary-adrenal (HPA) axis under basal conditions, in particular the role of the mineralocorticoid receptor. Blood samples were collected every 5 min from conscious rats at the diurnal
Rita Berardelli et al.
European journal of endocrinology, 162(6), 1067-1074 (2010-03-12)
Mineralocorticoid receptors (MRs) in the hippocampus display an important role in the control of the hypothalamic-pituitary-adrenal (HPA) axis, mediating the proactive feedback of glucocorticoids, which maintains the basal HPA activity. The systemic administration of MR antagonists enhances spontaneous and CRH-stimulated
Monica Minnaard-Huiban et al.
Endocrinology, 149(1), 28-31 (2007-09-22)
Reversal of cardiac fibrosis is a major determinant of the salutary effects of mineralocorticoid receptor antagonists in heart failure. Recently, R-fadrozole was coined as an aldosterone biosynthesis inhibitor, offering an appealing alternative to mineralocorticoid receptor antagonists to block aldosterone action.
Caroline Rugale et al.
Clinical and experimental pharmacology & physiology, 35(4), 412-415 (2008-03-01)
1. Time course of renal alterations associated with long-term (since weaning) administration of a high sodium (HS, 8% NaCl) diet was assessed in Sprague-Dawley rats. Reversal by acute administration of the mineralocorticoid receptor antagonist, potassium canrenoate (40 mg/kg, i.p.) or
Wenxia Chai et al.
Journal of hypertension, 28(5), 1044-1053 (2010-02-25)
To test whether glucocorticoids act as the endogenous agonist of cardiac mineralocorticoid receptors, we evaluated the cardiac effects of aldosterone and corticosterone and cardiac steroidogenesis vs. steroid uptake from plasma. Both corticosterone and aldosterone increased left ventricular pressure in the
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico